Caribou Biosciences (CRBU) Total Liabilities (2020 - 2026)

Caribou Biosciences (CRBU) has 7 years of Total Liabilities data on file, last reported at $47.0 million in Q1 2026.

• On a quarterly basis, Total Liabilities fell 16.75% year-over-year to $47.0 million in Q1 2026; TTM through Mar 2026 was $47.0 million, a 16.75% decrease from a year earlier, with the FY2025 full-year figure at $53.2 million, down 11.88% from the prior year.
• Total Liabilities for Q1 2026 stood at $47.0 million, down from $53.2 million in the prior quarter.
• Over the last five years, Total Liabilities for CRBU reached as high as $80.2 million in Q2 2023 and fell as low as $47.0 million in Q1 2026.
• Historically, Total Liabilities has averaged $63.6 million across 5 years, with a median of $63.1 million in 2024.
• Across the five-year window, Total Liabilities jumped 33.67% in 2022 and slipped 22.09% in 2024, its largest moves.
• Year by year, Total Liabilities stood at $72.9 million in 2022, then slipped by 12.46% to $63.8 million in 2023, then fell by 5.4% to $60.4 million in 2024, then slipped by 11.88% to $53.2 million in 2025, then retreated by 11.68% to $47.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $47.0 million in Q1 2026, $53.2 million in Q4 2025, and $53.1 million in Q3 2025.